In clinical studies, Relistor significantly decreased the constipating effects of opioids without interfering with pain relief. Wyeth expects to make Relistor available in the US in early June, 2008.
Bernard Poussot, president and CEO of Wyeth, said: “As Wyeth’s third new medicine to receive FDA approval in 2008, Relistor is an excellent example of Wyeth’s continuing commitment to develop and deliver medicines that work in novel ways and provide important new treatment options for patients.”